Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Immunovia invited to present at Jefferies 2018 London Healthcare Conference

November 13, 2018

LUND, Sweden — Immunovia (Nasdaq Stockholm: IMMNOV), today announced that the Company has been invited to present at the Jefferies 2018 London Healthcare Conference on November 14 at 2pm local time (GMT). Mats Grahn, CEO will present the IMMray™ antibody biomarker platform development pipeline and commercialisation strategies.

A live audio webcast of the presentation can be accessed via The webcast will be archived shortly afterwards under “Presentations” in the Investors section of the Company’s website at and be available for approximately 90 days.

For more information, please contact:

Mats Grahn

Chief Executive Officer, CEO, Immunovia

Tel.: +46-70-5320230


About Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source:

Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit


Press release Immunovia presentation at Jefferies